Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexpramipexole in severe eosinophilic asthma
NCT06388889Phase 3Terminated
- Sponsor
- Areteia Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of dexpramipexole in eosinophilic asthma (EA), sponsored by Areteia Therapeutics. Primary endpoints: Treatment Emergent Adverse Event at 52 weeks, Potentially Clinically Significant Postbaseline Changes in Clinical Laboratory Evaluations at 52 weeks and 2 more. Started Jun 2024; status: terminated.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT06388889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388889.